Safe use of intravesical bacillus Calmette-Guérin immunotherapy for bladder cancer during breastfeeding: a case report.
Erol BarburTunkut DogancaCan ObekPublished in: Immunotherapy (2022)
It is unknown whether intravesical bacillus Calmette-Guérin (BCG) is excreted in human breast milk. The US FDA advocates ceasing nursing due to potential adverse reactions. A lactating woman with bladder cancer who elected to receive intravesical immunotherapy with BCG and denied having ceased nursing her newborn is reported. A 42-year-old woman presented with macroscopic hematuria in the 36th week of her pregnancy. Imaging revealed a mass in the bladder. Cystoscopy and resection were performed after childbirth. Pathological examination revealed pT1 urothelial carcinoma. After a thorough discussion of the treatment options, the patient elected intravesical BCG. The infant received intradermal BCG vaccination 2 weeks before the treatment. As a result, the patient could breastfeed without any inadvertent sequela on herself or the baby.
Keyphrases
- muscle invasive bladder cancer
- case report
- healthcare
- endothelial cells
- mental health
- single cell
- high resolution
- urinary tract
- quality improvement
- preterm infants
- bacillus subtilis
- emergency department
- preterm birth
- heat stress
- induced pluripotent stem cells
- combination therapy
- dairy cows
- pregnancy outcomes
- photodynamic therapy
- electronic health record
- smoking cessation
- human health
- placebo controlled